Milliman, Inc., a premier global consulting and actuarial firm, today released…

Milliman, Inc., a premier global actuarial, consulting, and risk management firm…

Milliman, Inc., a premier global consulting and actuarial firm, today announced…

Milliman, Inc., the premier global consulting and actuarial firm, is providing…

We break down the top reasons insurers are shifting to ESG investing strategies.

The glucagon-like peptide-1 (GLP-1) receptor agonist drug class—which includes diabetes drugs Wegovy and Ozempic—is proving effective at managing obesity, leading to surging demand.

With U.S. inflation hitting a 40-year high, workers' compensation claims could be heavily affected in the upcoming years.

Given the medical costs of nonfatal firearm injuries, healthcare stakeholders have an interest in supporting further research to mitigate firearm injury risk.

The U.S. residential real estate market likely has not fully accounted for the financial costs of flooding. This graphic illustrates the potential cost of unpriced flood risk.

Smart infrastructure systems, in which technology is used to support roads, buildings, parking, utilities, and other city-managed systems, have the potential to make cities better places to live and more efficient.

As climate change exacerbates extreme heat and drought in areas like Australia and California, catastrophic fires are becoming more frequent and more intense.

Healthcare costs are back on the rise, projected in 2021 to grow by 8.4% to $28,256 for a family of four, versus a 4.2% decrease from 2019 to 2020, according to the Milliman Medical Index.

To better understand racial disparities in diabetes care, Milliman examined the utilization of three preventive diabetes services for both Black and white Medicare FFS beneficiaries.

This graph shows preventive services with the slowest growth in utilization between 2014 and 2017, across the Individual, Employer-based, Medicare, and Medicaid markets.

This graphic shows preventive services with the fastest growth in utilization between 2014 and 2017, across the Individual, Employer-based, Medicare, and Medicaid markets.